China’s pharmaceutical industry, whose revenue is projected to rise by 50 per cent between 2024 and 2030, has emerged as a new growth engine for the national economy as leading players ramp up investment in research and production.The country’s drug and medical device businesses were forecast to top US$2.1 trillion in revenue by 2030 and US$3.2 trillion annually by 2050, according to estimates by UBS. In 2024, the sector generated about US$1.4 trillion in sales.“An ageing population offers the...